Cited 26 times in
Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.contributor.author | 김범석 | - |
dc.contributor.author | 김순일 | - |
dc.contributor.author | 김유선 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이주한 | - |
dc.contributor.author | 허규하 | - |
dc.date.accessioned | 2017-11-02T08:33:24Z | - |
dc.date.available | 2017-11-02T08:33:24Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0931-0509 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154605 | - |
dc.description.abstract | BACKGROUND: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy. Although rituximab is increasingly used for desensitization of ABO-incompatible or positive crossmatch kidney transplantation, the risk of HBV reactivation in hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (anti-HBc)-positive kidney transplant patients receiving rituximab desensitization remains undetermined. METHODS: We analysed 172 resolved HBV patients who underwent living donor kidney transplantation between 2008 and 2014. Patients were divided into rituximab ( n = 49) or control ( n = 123) groups. All patients were observed for HBV reactivation, which was defined as the reappearance of hepatitis B surface antigen or HBV DNA. RESULTS: During the follow-up period (median, 58 months; range, 4-95 months), five patients (10.2%) in the rituximab group and two patients (1.6%) in the control group experienced HBV reactivation (P = 0.003). In the rituximab group, two patients experienced HBV-related severe hepatitis, and one patient died due to hepatic failure. The median time from rituximab desensitization to HBV reactivation was 11 months (range, 5-22 months). By contrast, no patients in the control group experienced severe hepatitis. The status of hepatitis B surface antibody was similar between groups. Rituximab desensitization [hazard ratio (HR), 9.18; 95% confidence interval (CI), 1.74-48.86; P = 0.009] and hepatitis B surface antibody status (HR, 4.74; 95% CI, 1.05-21.23, P = 0.04) were significant risk factors for HBV reactivation. CONCLUSIONS: Rituximab desensitization for incompatible kidney transplantation significantly increased the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients. Therefore, close monitoring of HBV DNA is required in these patients. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | NEPHROLOGY DIALYSIS TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Drug Resistance, Viral* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B/blood | - |
dc.subject.MESH | Hepatitis B/diagnosis | - |
dc.subject.MESH | Hepatitis B/etiology | - |
dc.subject.MESH | Hepatitis B/transmission* | - |
dc.subject.MESH | Hepatitis B Antibodies/blood* | - |
dc.subject.MESH | Hepatitis B Surface Antigens/blood* | - |
dc.subject.MESH | Hepatitis B virus/physiology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Transplantation/adverse effects* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Rituximab/pharmacology* | - |
dc.subject.MESH | Transplant Recipients | - |
dc.subject.MESH | Virus Activation/drug effects* | - |
dc.title | Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Juhan Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Kyu Ha Huh | - |
dc.contributor.googleauthor | Beom Seok Kim | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Soon Il Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Yu Seun Kim | - |
dc.identifier.doi | 10.1093/ndt/gfw455 | - |
dc.contributor.localId | A00488 | - |
dc.contributor.localId | A00649 | - |
dc.contributor.localId | A00785 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03163 | - |
dc.contributor.localId | A04344 | - |
dc.contributor.localId | A00424 | - |
dc.relation.journalcode | J02316 | - |
dc.identifier.eissn | 1460-2385 | - |
dc.identifier.pmid | 28339910 | - |
dc.identifier.url | https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfw455 | - |
dc.subject.keyword | hepatitis B virus | - |
dc.subject.keyword | immunosuppression | - |
dc.subject.keyword | kidney transplantation | - |
dc.subject.keyword | reactivation | - |
dc.subject.keyword | rituximab | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.alternativeName | Kim, Beom Seok | - |
dc.contributor.alternativeName | Kim, Soon Il | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Ju Han | - |
dc.contributor.alternativeName | Huh, Kyu Ha | - |
dc.contributor.affiliatedAuthor | Kim, Beom Seok | - |
dc.contributor.affiliatedAuthor | Kim, Soon Il | - |
dc.contributor.affiliatedAuthor | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Ju Han | - |
dc.contributor.affiliatedAuthor | Huh, Kyu Ha | - |
dc.contributor.affiliatedAuthor | Kim, Myoung Soo | - |
dc.citation.title | Nephrology Dialysis Transplantation | - |
dc.citation.volume | 32 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 722 | - |
dc.citation.endPage | 729 | - |
dc.identifier.bibliographicCitation | NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol.32(4) : 722-729, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 43660 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.